Radiopharm Theranostics Limited
RADX
$4.36
$0.369.00%
| Weiss Ratings | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.84% | |||
| 30-Day Total Return | -14.68% | |||
| 60-Day Total Return | -19.26% | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -6.03% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -92.13% | |||
| 52-Week Low % Change | 14.41% | |||
| Price | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $50.82 | |||
| 52-Week Low Price | $3.50 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | Dec 06, 2024 | |||
| Valuation | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 29.48M | |||
| Enterprise Value | 6.84M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.04 | |||
| Earnings Per Share Growth | -53.93% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 40,000.00 | |||
| Price/Book (Q) | 266.67 | |||
| Enterprise Value/Revenue (TTM) | 30.58 | |||
| Price | $4.36 | |||
| Enterprise Value/EBITDA (TTM) | -0.31 | |||
| Enterprise Value/EBIT | -0.29 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.84B | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 61 3 9824 5254 | |||
| Address | 62 Lygon Street Carlton, VIC 3053 | |||
| Website | www.radiopharmtheranostics.com | |||
| Country | Australia | |||
| Year Founded | 2021 | |||
| Profitability | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -10,631.50% | |||
| Profit Margin | -12,350.84% | |||
| Management Effectiveness | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -29.64% | |||
| Return on Equity | -- | |||
| Income Statement | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.11M | |||
| Total Revenue (TTM) | 223.80K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -14.11M | |||
| EBITDA (TTM) | -21.77M | |||
| EBIT (TTM) | -23.79M | |||
| Net Income (TTM) | -27.64M | |||
| Net Income Avl. to Common (TTM) | -27.64M | |||
| Total Revenue Growth (Q YOY) | -40.05% | |||
| Earnings Growth (Q YOY) | 20.67% | |||
| EPS Diluted (TTM) | -0.04 | |||
| EPS Diluted Growth (Q YOY) | 85.96% | |||
| Balance Sheet | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 22.55M | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 27.45M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 32.18M | |||
| Current Ratio (Q) | 3.374 | |||
| Book Value Per Share (Q) | $0.02 | |||
| Total Assets (Q) | 57.21M | |||
| Total Current Liabilities (Q) | 8.14M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 25.03M | |||
| Total Common Equity (Q) | 32.92M | |||
| Cash Flow | RADX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 1.98M | |||
| Cash from Financing (TTM) | 42.56M | |||
| Net Change in Cash (TTM) | 22.79M | |||
| Levered Free Cash Flow (TTM) | -12.00M | |||
| Cash from Operations (TTM) | -22.06M | |||
